OT Staff Reports


Comparing suitable naïve versus pre-treated DME patients

September 10, 2021

Javier Zarranz-Ventura MD, PhD, FEBO, discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.

Targeting neurodegenerative diseases with risuteganib as treatment therapy

May 03, 2021

Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.